Osivax Receives $19.5M BARDA Award to Advance Next-Generation Influenza Vaccine for Pandemic and Seasonal Preparedness Funding to accelerate development of Osivax’ broad-spectrum influenza A vaccine candidate, OVX836 Lyon, France and Liège, Belgium – August 26, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced it has …
Archives de l’auteur : Marianne Duparc
Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal
Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal Co-administration of OVX836 with seasonal inactivated influenza vaccine (Fluarix® Tetra) was well-tolerated and demonstrated a favorable safety profile Robust complementary immune responses were induced, with no major interference observed Lyon, France – July 10, 2025 – Osivax, a biopharmaceutical company …
Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836
Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 Final results expected in H2 2025 Lyon, France – June 5, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that all participants have completed their final visit …
Osivax Secures Strategic Funding to Accelerate the Development of its Influenza Vaccine Candidates
Osivax Secures Strategic Funding to Accelerate the Development of its Influenza Vaccine Candidates First Close of Series B financing raises €10 million Meiji Seika Pharma Co., Ltd joins as new international investor Proceeds will accelerate preclinical and clinical development of its broad-spectrum influenza vaccine candidates Lyon, France – March 4, 2025 – Osivax, a …
I4ID 2024
Lyon, France – PosterSéverine Valsesia, Immuno R&D engineer, to present a poster entitled “A mix of OVX836, a NP-based influenza vaccine candidate, with a commercial seasonal vaccine is immunogenic and synergistically protective in mice”. François Fasquelle, Clinical Immunology Project Manager, to present a poster entitled “OVX836, a NP-based broad-spectrum influenza vaccine candidate, is safe, immunogenic …
Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836
Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836 Phase 2a study to evaluate safety and immunogenicity of a booster dose of influenza vaccine candidate OVX836, three to five years after initial administration Enrollment of over 150 participants anticipated in Belgium Lyon, France – November 14, 2024 – Osivax, a biopharmaceutical …
World Vaccines Congress Europe 2024
Barcelona, Spain – Oral PresentationNicola Groth, Chief Medical Officer, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Update of OVX836, a Novel Broad-Spectrum Type A Influenza Vaccine Candidate”.
Options XII for the Control of Influenza
Brisbane, Australia – Oral Presentation and PostersAlexandre Le Vert, Chief Executive Officer & Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “OVX836, A NP-Based Universal Influenza Vaccine Candidate, Triggers Effector CD4+ and Cytotoxic CD8+ T-Cells in Healthy Adults”. Delphine Guyon-Gellin, Chief of Business Development & Chief Operating …
Continuer la lecture « Options XII for the Control of Influenza »
Osivax and KM Biologics Enter Exclusive License Option Agreement for Broad-Spectrum “Universal” Influenza Vaccine in Japan
Osivax and KM Biologics Enter Exclusive License Option Agreement for Broad-Spectrum “Universal” Influenza Vaccine in Japan KM Biologics, a Meiji Group company, has received an exclusive option to exercise an exclusive license for the development, manufacturing and commercialization of Osivax’s broad-spectrum “universal” influenza vaccine candidates in Japan Osivax is to receive upfront payment for execution …
Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033
Osivax completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033 48 healthy volunteers enrolled in first-in-human trial Topline data read-out expected by Q4 2024 Lyon, France – June 25, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that it has completed …